Phase I trial of combretastatin A4 phosphate (CA4P) in combination with bevacizumab in patients with advanced cancer
Options
Publisher DOI
PubMed ID
22645052
Description
The vascular disrupting agent (VDA) combretastatin A4 phosphate (CA4P) induces significant tumor necrosis as a single agent. Preclinical models have shown that the addition of an anti-VEGF antibody to a VDA attenuates the revascularization of the surviving tumor rim and thus significantly increases antitumor activity.
Date of Publication
2012
Publication Type
Article
Language(s)
en
Contributor(s)
Nathan, Paul | |
Padhani, Anwar R | |
Koh, Dow-Mu | |
Ng, Matthew | |
Collins, David J | |
Harris, Adrian | |
Carden, Craig | |
Smythe, Jon | |
Fisher, Nita | |
Taylor, N Jane | |
Stirling, J James | |
Lu, Shiao-Ping | |
Leach, Martin O | |
Rustin, Gordon J S | |
Judson, Ian |
Additional Credits
Universitätsklinik für Medizinische Onkologie
Series
Clinical cancer research
Publisher
American Association for Cancer Research
ISSN
1078-0432
Access(Rights)
metadata.only